WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004003170) AGENTS CAPABLE OF INHIBITING RAS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/003170    International Application No.:    PCT/US2003/020684
Publication Date: 08.01.2004 International Filing Date: 30.06.2003
Chapter 2 Demand Filed:    08.12.2003    
IPC:
A61K 38/00 (2006.01), A61K 48/00 (2006.01), C07K 14/47 (2006.01), C07K 14/82 (2006.01)
Applicants: THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street, Baltimore, MD 21218 (US) (For All Designated States Except US).
LEVIN, David, E. [US/US]; (US) (For US Only).
SOBERING, Andrew, K. [US/FR]; (FR) (For US Only)
Inventors: LEVIN, David, E.; (US).
SOBERING, Andrew, K.; (FR)
Agent: VINCENT, Matthew, P.; Ropes & Gray LLP, One International Place, Boston, MA 02110-2624 (US)
Priority Data:
60/392,355 28.06.2002 US
Title (EN) AGENTS CAPABLE OF INHIBITING RAS AND USES THEREOF
(FR) AGENTS CAPABLES D'INHIBER RAS ET LEURS UTILISATIONS
Abstract: front page image
(EN)This invention provides an agent capable of blocking the interaction between GTP-Ras and ERI1, wherein ERI1 is a protein comprising amino acids, the sequence of which amino acids is set forth in SEQ ID NO:7. In one embodiment, the agent comprises at least a portion of the ERI1 sequence. This invention provides a nucleic acid which encodes such agent. This invention also provides uses of the agent for treating cancer.
(FR)Cette invention porte sur un agent capable de bloquer l'interaction entre GTP-Ras et ERI1, ERI1 étant une protéine comprenant des amino-acides dont la séquence est indiquée comme suit : SEQ ID NO:7. Selon un mode de réalisation, l'agent comprend au moins une partie de la séquence ERI1. Cette invention porte sur un acide nucléique qui code cet agent, et sur l'utilisation de cet agent dans le traitement du cancer.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)